PDCD1 and cancer: Four diagnostic companion PD-L1 immunohistochemistry tests have been approved for use with PD-1/PD-L1 blocking antibodies in selected cancer subtypes (Dako platform 22C3, 28-8 and Ventana platform SP263, SP142) [6].